Literature DB >> 17951402

Normalization of the ovarian cancer microenvironment by SPARC.

Neveen Said1, Matthew J Socha, Jeffrey J Olearczyk, Ahmed A Elmarakby, John D Imig, Kouros Motamed.   

Abstract

Malignant ascites is a major source of morbidity and mortality in ovarian cancer patients. It functions as a permissive reactive tumor-host microenvironment and provides sustenance for the floating tumor cells through a plethora of survival/metastasis-associated molecules. Using a syngeneic, immunocompetent model of peritoneal ovarian carcinomatosis in SP(-/-) mice, we investigated the molecular mechanisms implicated in the interplay between host secreted protein acidic and rich in cysteine (SPARC) and ascitic fluid prosurvival/prometastasis factors that result in the significantly augmented levels of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMP). Ascitic fluid-enhanced ID8 invasiveness was mediated through VEGF via a positive feedback loop with MMP-2 and MMP-9 and through activation of alpha(v) and beta(1) integrins. Host SPARC down-regulated the VEGF-MMP axis at the transcriptional and posttranscriptional levels. In vitro, SPARC attenuated the basal as well as VEGF-induced integrin activation in tumor cells. SPARC inhibited the VEGF- and integrin-mediated ID8 proliferation in vitro and significantly suppressed their tumorigenicity in vivo. Relative to SP(+/+), SP(-/-) ascitic fluid contained significantly higher levels of bioactive lipids and exerted stronger chemotactic, proinvasive, and mitogenic effects on ID8 cells in vitro. SP(-/-) ascites also contained high levels of interleukin-6, macrophage chemoattractant protein-1, and 8-isoprostane (prostaglandin F(2)alpha) that were positively correlated with extensive infiltration of SP(-/-) ovarian tumors and ascites with macrophages. In summary, our findings strongly suggest that host SPARC normalizes the microenvironment of ovarian cancer malignant ascites through down-regulation of the VEGF-integrin-MMP axis, decreases the levels and activity of bioactive lipids, and ameliorates downstream inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951402     DOI: 10.1158/1541-7786.MCR-07-0001

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  32 in total

1.  RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.

Authors:  Neveen Said; Marta Sanchez-Carbayo; Steven C Smith; Dan Theodorescu
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

2.  Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing.

Authors:  Donald M Lamkin; Susan K Lutgendorf; David Lubaroff; Anil K Sood; Terry G Beltz; Alan Kim Johnson
Journal:  Brain Behav Immun       Date:  2010-12-21       Impact factor: 7.217

3.  SPARC expression induces cell cycle arrest via STAT3 signaling pathway in medulloblastoma cells.

Authors:  Chandramu Chetty; Ranadheer Dontula; Purnachandra Nagaraju Ganji; Meena Gujrati; Sajani S Lakka
Journal:  Biochem Biophys Res Commun       Date:  2011-12-20       Impact factor: 3.575

4.  Loss of SPARC in bladder cancer enhances carcinogenesis and progression.

Authors:  Neveen Said; Henry F Frierson; Marta Sanchez-Carbayo; Rolf A Brekken; Dan Theodorescu
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

Review 5.  The SPARC protein: an overview of its role in lung cancer and pulmonary fibrosis and its potential role in chronic airways disease.

Authors:  Sharon L I Wong; Maria B Sukkar
Journal:  Br J Pharmacol       Date:  2016-11-25       Impact factor: 8.739

6.  SPARC ameliorates ovarian cancer-associated inflammation.

Authors:  Neveen A Said; Ahmed A Elmarakby; John D Imig; David J Fulton; Kouros Motamed
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

7.  Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer.

Authors:  Jian-fang Liang; Hong-kun Wang; Hong Xiao; Ning Li; Cai-xia Cheng; Yu-ze Zhao; Yan-b Ma; Jian-zhong Gao; Rui-bing Bai; Hui-xia Zheng
Journal:  J Exp Clin Cancer Res       Date:  2010-06-16

8.  Development of a syngeneic mouse model of epithelial ovarian cancer.

Authors:  Bridget A Quinn; Fang Xiao; Laura Bickel; Lainie Martin; Xiang Hua; Andres Klein-Szanto; Denise C Connolly
Journal:  J Ovarian Res       Date:  2010-10-19       Impact factor: 4.234

9.  Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells.

Authors:  Justyna Mikuła-Pietrasik; Paweł Uruski; Kinga Matuszkiewicz; Sebastian Szubert; Rafał Moszyński; Dariusz Szpurek; Stefan Sajdak; Andrzej Tykarski; Krzysztof Książek
Journal:  Cell Oncol (Dordr)       Date:  2016-07-21       Impact factor: 6.730

10.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.